JP2005537028A - ヒト乳頭腫ウイルス感染症を治療する方法及び材料 - Google Patents

ヒト乳頭腫ウイルス感染症を治療する方法及び材料 Download PDF

Info

Publication number
JP2005537028A
JP2005537028A JP2004549835A JP2004549835A JP2005537028A JP 2005537028 A JP2005537028 A JP 2005537028A JP 2004549835 A JP2004549835 A JP 2004549835A JP 2004549835 A JP2004549835 A JP 2004549835A JP 2005537028 A JP2005537028 A JP 2005537028A
Authority
JP
Japan
Prior art keywords
nucleic acid
hpv
acid molecule
sequence
library
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004549835A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005537028A5 (https=
Inventor
ゲイリー エイ． クラウソン
ウェイ−ホァ パン
ニール クリステンセン
ダイアン ティブトット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Penn State Research Foundation
Original Assignee
Penn State Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Penn State Research Foundation filed Critical Penn State Research Foundation
Publication of JP2005537028A publication Critical patent/JP2005537028A/ja
Publication of JP2005537028A5 publication Critical patent/JP2005537028A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2004549835A 2002-06-26 2003-06-26 ヒト乳頭腫ウイルス感染症を治療する方法及び材料 Withdrawn JP2005537028A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39179502P 2002-06-26 2002-06-26
US41799702P 2002-10-14 2002-10-14
US44906603P 2003-02-21 2003-02-21
PCT/US2003/020340 WO2004002416A2 (en) 2002-06-26 2003-06-26 Methods and materials for treating human papillomavirus infections

Publications (2)

Publication Number Publication Date
JP2005537028A true JP2005537028A (ja) 2005-12-08
JP2005537028A5 JP2005537028A5 (https=) 2006-01-26

Family

ID=30003830

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004549835A Withdrawn JP2005537028A (ja) 2002-06-26 2003-06-26 ヒト乳頭腫ウイルス感染症を治療する方法及び材料

Country Status (6)

Country Link
US (1) US7704965B2 (https=)
EP (1) EP1539245A2 (https=)
JP (1) JP2005537028A (https=)
AU (1) AU2003256325A1 (https=)
CA (1) CA2491034A1 (https=)
WO (1) WO2004002416A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016034975A (ja) * 2011-08-19 2016-03-17 オーストリッチファーマ株式会社 抗体および抗体含有組成物
JP2022512929A (ja) * 2018-11-02 2022-02-07 ユニヴァーシティ・オブ・エセックス・エンタープライジズ・リミテッド 酵素核酸分子

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061804A1 (en) 1999-04-14 2000-10-19 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
JP2006523103A (ja) * 2003-02-21 2006-10-12 ザ ペン ステイト リサーチ ファウンデーション Ｒｎａ干渉組成物および方法
WO2007121893A1 (en) * 2006-04-21 2007-11-01 Transgene S.A. Method for treating hpv infected patients
CA2712056C (en) 2007-01-16 2016-06-21 The University Of Queensland Method of inducing an immune response
CA2619157A1 (en) * 2007-02-08 2008-08-08 Michel Serrano Anti-human papillomas virus composition
US7897833B2 (en) * 2007-04-18 2011-03-01 Kao Corporation Animal model for pigment spots
US7973211B2 (en) * 2007-04-18 2011-07-05 Kao Corporation Animal model for hyperpigmentation
JP6153866B2 (ja) 2010-05-25 2017-06-28 キアゲン ガイサーズバーグ アイエヌシー． 迅速なハイブリッド捕捉アッセイ、及び関連する戦略的に切断されたプローブ
WO2012016139A2 (en) * 2010-07-29 2012-02-02 Sirnaomics, Inc. Sirna compositions and methods for treatment of hpv and other infections
CN102228698B (zh) * 2011-06-28 2013-12-18 广西医科大学附属肿瘤医院 Hpv58型治疗性复合基因疫苗及其构建方法
CN104404076B (zh) * 2014-11-04 2017-10-03 珠海雅马生物工程有限公司 利用锌指核酸酶敲除人乳头瘤病毒e6e7基因的方法
WO2017214449A1 (en) * 2016-06-09 2017-12-14 The Regents Of The University Of California Inhibition of e5 in hpv-infected cells

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4511713A (en) 1980-11-12 1985-04-16 The Johns Hopkins University Process for selectively controlling unwanted expression or function of foreign nucleic acids in animal or mammalian cells
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
WO1983001451A1 (en) 1981-10-23 1983-04-28 Molecular Biosystems Inc Oligonucleotide therapeutic agent and methods of making same
FR2536278A1 (fr) 1982-11-18 1984-05-25 Dupont Michele Nouvelle composition therapeutique utile notamment pour la cicatrisation des plaies
NZ209840A (en) 1983-10-17 1988-11-29 Kaji Akira A method of inhibiting viral propagation by hybridising dna with the viral rna thus blocking its action
US5272065A (en) 1983-10-20 1993-12-21 Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5190931A (en) 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US4740463A (en) 1984-04-13 1988-04-26 Massachusetts Institute Of Technology Methods and artificial genes for antagonizing the function of an oncogene
US5411857A (en) 1985-07-31 1995-05-02 Institut Nationale De La Sante Probes for papillomaviruses and an in vitro diagnostic procedure for papilloma infections
CA1276575C (fr) 1984-11-30 1990-11-20 Sylvie Beaudenon Sondes a papillomavirus et procede de diagnostic in vitro d'infections a papillomavirus
US5876922A (en) 1985-07-31 1999-03-02 Institute Pasteur Papillomavirus probe and a process for in vitro diagnosis of papillomavirus infections
EP0217919B1 (en) 1985-04-04 1992-08-05 Georgetown University Type-specific papillomavirus dna sequences and peptides
AU615159B2 (en) 1986-03-21 1991-09-26 F. Hoffmann-La Roche Ltd Determined dna sequences derived from a papillomavirus genome, their uses for in vitro diagnostic purposes and the production of antigenic compositions
US4814268A (en) 1986-10-06 1989-03-21 Kreider John W Methods for propagating fastidious human viruses and for producing purified suspensions thereof
US5071757A (en) 1986-10-06 1991-12-10 Kreider John W Methods for propagating fastidious human viruses and for producing purified suspensions thereof
US4849332A (en) 1987-05-26 1989-07-18 Life Technologies, Inc. Human papillomavirus 35 nucleic acid hybridization probes and methods for employing the same
US4849334A (en) 1987-06-09 1989-07-18 Life Technologies, Inc. Human papillomavirus 43 nucleic acid hybridization probes and methods for employing the same
US4849331A (en) 1987-06-09 1989-07-18 Life Technologies, Inc. Human papillomavirus 44 nucleic acid hybridization probes and methods for employing the same
US4908306A (en) 1987-06-12 1990-03-13 Life Technologies, Inc. Human papillomavirus 56 nucleic acid hybridization probes and methods for employing the same
DE3722968A1 (de) 1987-07-11 1989-01-19 Behringwerke Ag Humaner papillomvirus typ 41, seine dna und die dafuer kodierenden proteine
FR2629458B2 (fr) 1987-07-31 1991-08-09 Ire Celltarg Sa Nouvelles sondes d'acides nucleiques specifiques de differents types de virus de papillome humain
CA1339596C (en) 1987-08-07 1997-12-23 New England Medical Center Hospitals, Inc. Viral expression inhibitors
ATE151467T1 (de) 1987-11-30 1997-04-15 Univ Iowa Res Found Durch modifikationen an der 3'-terminalen phosphodiesterbindung stabilisierte dna moleküle, ihre verwendung als nukleinsäuresonden sowie als therapeutische mittel zur hemmung der expression spezifischer zielgene
FR2632956B2 (fr) 1988-05-13 1991-07-12 Pasteur Institut Sondes a papillomavirus hpv49, hpv50, hpv54, hpv55; produits genetiquement et immunologiquement lies a ce papillomavirus hpv49, hpv50, hpv54, hpv55; procede de diagnostic in vitro d'infections a papillomavirus et d'immunisation in vivo contre ces papillomavirus
DE3826793A1 (de) 1988-08-06 1990-03-08 Behringwerke Ag Humaner papillomvirus typ 57, seine dna und die davon kodierten proteine
CA1339729C (en) 1988-10-26 1998-03-17 Wayne D. Lancaster Human papillomavirus type 52 dna sequences and methods for employing thesame
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5776502A (en) 1989-07-18 1998-07-07 Oncogene Science, Inc. Methods of transcriptionally modulating gene expression
IT1232318B (it) 1989-09-07 1992-01-28 Crinos Industria Farmaco Composizioni ad uso topico contenenti acidi nucleici depolimerizzati per la cosmesi della pelle e del corpo.
US5053024A (en) * 1989-10-23 1991-10-01 Israel Dvoretzky Application system and method for treating warts
US5457189A (en) 1989-12-04 1995-10-10 Isis Pharmaceuticals Antisense oligonucleotide inhibition of papillomavirus
US5811232A (en) 1989-12-04 1998-09-22 Isis Pharmaceuticals, Inc. Oligonucleotides for Papillomavirus
US5756282A (en) 1989-12-04 1998-05-26 Isis Pharmaceuticals, Inc. Oligonucleotides for the diagnosis of papillomavirus
US6174870B1 (en) * 1989-12-04 2001-01-16 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of papillomavirus
CA2052413C (en) 1990-09-28 2004-07-13 Jeffrey L. Joseph Nucleotides sequences useful as type-specific probes, pcr primers and lcr probes for the amplifications and detection of human papilloma virus, and related kits and methods
FR2670797A1 (fr) 1990-12-20 1992-06-26 Pasteur Institut Sequences d'adn determinees derivees du genome du papillomavirus hpv39, application de ces sequences au diagnostic in vitro d'infection par ce papillomavirus, et a la production de composition immunogene.
US5219990A (en) 1991-01-28 1993-06-15 Biogen, Inc. Papillomavirus e2 trans-activation repressors
FR2678284B1 (fr) 1991-06-28 1993-10-08 Pasteur Institut Sequences d'adn derivees du genome du papillomavirus hpv42, application de ces sequences au diagnostic in vitro d'infection par ce papillomavirus et a la production de compositions immunogenes.
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5470577A (en) 1993-07-07 1995-11-28 Trustees Of Boston University Stimulation of tanning by DNA fragments or single-stranded DNA
WO1995002698A1 (en) 1993-07-12 1995-01-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
DK0721457T3 (da) 1993-09-24 1999-11-08 Edward I Budowsky 2',5'-Oligoadenylat-2',3'-cyclophosphater og 2',5'-oligo-adenylater med antipapillomavirusaktivitet
US5955597A (en) 1993-11-16 1999-09-21 Genta, Incorporated Chirally enriched synthetic phosphate oligomers
AU687492B2 (en) 1993-11-16 1998-02-26 Genta Incorporated Synthetic oligomers having phosphonate internucleosidyl linkages of undefined chirality mixed with non-phosphonate internucleosidyl linkages
NZ276968A (en) 1993-11-16 1998-04-27 Genta Inc Synthetic oligomers enriched for phosphonate internucleosidyl linkages of preselected chirality and their preparation
AU678085B2 (en) 1993-11-16 1997-05-15 Genta Incorporated Synthetic oligomers having chirally pure phosphonate internucleosidyl linkages mixed with non-phosphonate internucleosidyl linkages
US6060456A (en) 1993-11-16 2000-05-09 Genta Incorporated Chimeric oligonucleoside compounds
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
US6075012A (en) 1994-02-11 2000-06-13 Life Technologies, Inc. Reagents for intracellular delivery of macromolecules
AU2584395A (en) 1994-04-26 1995-11-16 Genta Incorporated Antisense oligomers for inhibiting human papillomaviruses
DE4415743C2 (de) 1994-05-04 1996-10-10 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
US5543417A (en) 1994-10-21 1996-08-06 Merck & Co., Inc. Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
US5627159A (en) 1994-10-27 1997-05-06 Life Technologies, Inc. Enhancement of lipid cationic transfections in the presence of serum
US5807718A (en) * 1994-12-02 1998-09-15 The Scripps Research Institute Enzymatic DNA molecules
ES2323909T3 (es) 1994-12-24 2009-07-27 Cambridge University Technical Services Limited Mejoras introducidas en la funcion endometrial.
US5736392A (en) 1995-06-07 1998-04-07 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US5821050A (en) 1995-07-04 1998-10-13 Isis Pharmaceuticals, Inc. Drug screening assay for antiviral activity against papillomavirus
FR2737118B1 (fr) 1995-07-28 1997-09-05 Oreal Composition dermatologique ou pharmaceutique, procede de preparation et utilisation
US5824519A (en) 1995-11-08 1998-10-20 Medical University Of South Carolina Tissue-specific and target RNA-specific ribozymes
JP2000505418A (ja) 1996-01-26 2000-05-09 コドン・ファーマシューティカルズ・インコーポレイテッド オリゴヌクレオチド類縁体
US5981173A (en) 1996-02-14 1999-11-09 Institut Pasteur Genital human papillomavirus type 68a (HPV-68a), related to the potentially oncogenic HPV-39
US6022863A (en) 1996-05-21 2000-02-08 Yale University Regulation of gene expression
WO1998004575A2 (en) 1996-07-31 1998-02-05 Gilead Sciences, Inc. Lipophilic oligonucleotide analogs
EP1007735A1 (en) 1997-02-24 2000-06-14 TM Technologies Inc. Anti-sense oligonucleotide pharmacological agents
US6084090A (en) 1997-09-05 2000-07-04 The United States Of America As Represented By The Department Of Health And Human Services Human papilloma virus anti-sense oligonucleotides
DE69806024T2 (de) 1997-09-16 2003-02-13 Delft Diagnostic Laboratory B.V., Delft Erkennung und identifizierung von menschlichem papillomavirus durch pcr und typ-spezifischer reverser hybridisierung
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6087341A (en) 1998-02-12 2000-07-11 The Board Of Trustees Of The Leland Standford Junior University Introduction of nucleic acid into skin cells by topical application
DE69923172T2 (de) * 1998-04-29 2005-12-29 Medac Gesellschaft für klinische Spezialpräparate m.b.H Behandlung einer papillomavirusinfektion durch verwendung von mycobacterium
AU5298699A (en) * 1998-08-13 2000-03-06 Johnson & Johnson Research Pty. Limited Dnazymes and methods for treating hpv-related disorders
EP1728865A1 (en) 1998-09-04 2006-12-06 Aventis Pasteur Limited Treatment of cervical cancer
EP1151094A1 (en) 1998-12-07 2001-11-07 University College London Cervical cancer treatment
EP2314700A1 (en) * 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
WO2000060115A2 (en) 1999-04-02 2000-10-12 City Of Hope Method for identifying accessible binding sites on rna
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
WO2000061804A1 (en) * 1999-04-14 2000-10-19 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US20040259247A1 (en) * 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
EP1353935A4 (en) 2000-12-07 2005-02-23 Penn State Res Found SELECTION OF TARGET CATALYTIC NUCLEIC ACIDS ON INFECTIOUS AGENTS
CA2452653A1 (en) * 2001-07-17 2003-01-30 Anne Josephine Milner Silencing of gene expression by sirna
US6821523B2 (en) * 2002-06-21 2004-11-23 Dermatrends, Inc. Topical administration of pharmacologically active bases in the treatment of warts
JP2006523103A (ja) * 2003-02-21 2006-10-12 ザ ペン ステイト リサーチ ファウンデーション Ｒｎａ干渉組成物および方法

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016034975A (ja) * 2011-08-19 2016-03-17 オーストリッチファーマ株式会社 抗体および抗体含有組成物
US9828419B2 (en) 2011-08-19 2017-11-28 Ostrich Pharma Kk Antibody and antibody-containing composition
US10106599B2 (en) 2011-08-19 2018-10-23 Ostrich Pharma Kk Antibody and antibody-containing composition
JP2019006817A (ja) * 2011-08-19 2019-01-17 オーストリッチファーマ株式会社 抗体および抗体含有組成物
US10428138B2 (en) 2011-08-19 2019-10-01 Ostrich Pharma Kk Antibody and antibody-containing composition
US11041016B2 (en) 2011-08-19 2021-06-22 Ostrich Pharma Kk Compositions containing anti-HIV ostrich antibodies
JP2022512929A (ja) * 2018-11-02 2022-02-07 ユニヴァーシティ・オブ・エセックス・エンタープライジズ・リミテッド 酵素核酸分子
US12378559B2 (en) 2018-11-02 2025-08-05 University Of Essex Enterprises Limited Enzymatic nucleic acid molecules

Also Published As

Publication number Publication date
WO2004002416A3 (en) 2005-02-03
AU2003256325A1 (en) 2004-01-19
US7704965B2 (en) 2010-04-27
US20060058252A1 (en) 2006-03-16
EP1539245A2 (en) 2005-06-15
WO2004002416A2 (en) 2004-01-08
CA2491034A1 (en) 2004-01-08

Similar Documents

Publication Publication Date Title
US7704965B2 (en) Methods and materials for treating human papillomavirus infections
US20040209263A1 (en) Selection of catalytic nucleic acids targeted to infectious agents
US20150031871A1 (en) RNA-Mediated Gene Modulation
JP2019504868A (ja) レトロウイルス核酸配列の切除
JP2002542263A (ja) ポリヌクレオチド配列の機能を阻害するための方法および組成物
WO2000009673A1 (en) Dnazymes and methods for treating hpv-related disorders
JP6727381B2 (ja) Ｈｐｖ感染に係わる癌の治療用組成物
CA2226457C (en) Oligonucleotides specific for human papilloma virus
CA2516425A1 (en) Rna interference compositions and methods
JP2026502888A (ja) エピジェネティック調節因子の新規阻害剤
Clawson et al. Inhibition of papilloma progression by antisense oligonucleotides targeted to HPV11 E6/E7 RNA
Márquez-Gutiérrez et al. Effect of combined antisense oligodeoxynucleotides directed against the human papillomavirus type 16 on cervical carcinoma cells
CN115400222B (zh) 一种用于人乳头状瘤病毒感染治疗和预防的核酸多肽纳米药物组合物
Burley Loss of CTCF-YY1-mediated regulation of human papillomavirus oncogene transcription in HPV-driven disease
WO2022266287A1 (en) Compositions and methods to transfect, test, and treat skin cells
AU2002228756B2 (en) Selection of catalytic nucleic acids targeted to infectious agents
JP2004501614A (ja) Ｈｐｖ特異的ショートマー
JP2011190176A (ja) 肥満細胞の脱顆粒抑制剤
Wenn THE STUDY OF A NOVEL MIXED LINEAGE LEUKEMIA 5 ISOFORM AND ITS ASSOCIATION WITH HUMAN PAPILLOMAVIRUS 16/18-RELATED HUMAN CERVICAL CANCERS
WO2017214449A1 (en) Inhibition of e5 in hpv-infected cells
AU2002228756A1 (en) Selection of catalytic nucleic acids targeted to infectious agents
KR20180095694A (ko) 핵산 올리고머 및 이의 용도
WO2011046221A1 (ja) インターフェロン－αモジュレーター

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051006

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060626

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20080723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080724